TXG vs. SBRA

Last updated Jun 4, 2026

TXG (10x Genomics, Inc.) and SBRA (Sabra Health Care REIT, Inc.) are both stocks. TXG operates in Health Information Services (Healthcare), while SBRA operates in REIT - Healthcare Facilities (Real Estate). Over the past 5 years, TXG returned -29.15%/yr vs 8.95%/yr for SBRA. At a 0.17 correlation, their price movements are largely independent.

Performance

TXG vs. SBRA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in 10x Genomics, Inc. (TXG) and Sabra Health Care REIT, Inc. (SBRA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TXG achieves a 97.18% return, which is significantly higher than SBRA's -1.66% return.

TXG

• 1D: 4.72%
• 1M: 48.55%
• YTD: 97.18%
• 6M: 79.97%
• 1Y: 253.02%
• 3Y*: -16.17%
• 5Y*: -29.15%
• 10Y*: —

SBRA

• 1D: -2.58%
• 1M: -10.31%
• YTD: -1.66%
• 6M: -3.09%
• 1Y: 10.02%
• 3Y*: 25.72%
• 5Y*: 8.95%
• 10Y*: 6.25%

*Multi-year figures are annualized to reflect compound growth (CAGR)

TXG vs. SBRA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
TXG 10x Genomics, Inc.	97.18%	13.58%	-74.34%	53.57%	-75.54%	5.20%	85.70%	44.55%
SBRA Sabra Health Care REIT, Inc.	-1.66%	17.02%	31.23%	26.26%	0.38%	-16.16%	-11.33%	-3.19%

Correlation

The correlation between TXG and SBRA is -0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	-0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.09
Correlation (5Y) Calculated over the trailing 5-year period	0.18
Correlation (All Time) Calculated using the full available price history since Sep 13, 2019	0.17

The correlation between TXG and SBRA shifts across timeframes, from -0.07 (1 year) to 0.18 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap TXG : $4.13B SBRA : $4.63B
EPS TXG : -$0.18 SBRA : $0.63
PS Ratio TXG : 6.36 SBRA : 5.53
PB Ratio TXG : 5.07 SBRA : 1.66
Total Revenue (TTM) TXG : $638.78M SBRA : $812.84M
Gross Profit (TTM) TXG : $444.61M SBRA : $379.92M
EBITDA (TTM) TXG : -$5.89M SBRA : $438.08M

Return for Risk

TXG vs. SBRA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TXG

TXG Risk / Return Rank: 95
TXG Sharpe Ratio Rank: 97
TXG Sortino Ratio Rank: 94
TXG Omega Ratio Rank: 90
TXG Calmar Ratio Rank: 97
TXG Martin Ratio Rank: 95

SBRA

SBRA Risk / Return Rank: 54
SBRA Sharpe Ratio Rank: 58
SBRA Sortino Ratio Rank: 49
SBRA Omega Ratio Rank: 46
SBRA Calmar Ratio Rank: 56
SBRA Martin Ratio Rank: 62

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TXG vs. SBRA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Sabra Health Care REIT, Inc. (SBRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TXG	SBRA	Difference
Sharpe ratio: Return per unit of total volatility	3.81	0.51	+3.30
Sortino ratio: Return per unit of downside risk	3.91	0.83	+3.07
Omega ratio: Gain probability vs. loss probability	1.45	1.10	+0.35
Calmar ratio: Return relative to maximum drawdown	9.15	0.71	+8.44
Martin ratio: Return relative to average drawdown	21.17	2.39	+18.78
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TXG vs. SBRA - Sharpe Ratio Comparison

The current TXG Sharpe Ratio is 3.81, which is higher than the SBRA Sharpe Ratio of 0.51. The chart below compares the historical Sharpe Ratios of TXG and SBRA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	TXG	SBRA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.81	0.51	+3.30
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.43	0.34	-0.76
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.17	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.11	0.03	-0.14

Drawdowns

TXG vs. SBRA - Drawdown Comparison

The maximum TXG drawdown since its inception was -96.47%, roughly equal to the maximum SBRA drawdown of -99.49%. Use the drawdown chart below to compare losses from any high point for TXG and SBRA.

Drawdown Indicators

	TXG	SBRA	Difference
Max Drawdown Largest peak-to-trough decline	-96.47%	-99.49%	+3.02%
Max Drawdown (1Y) Largest decline over 1 year	-28.03%	-14.10%	-13.93%
Max Drawdown (3Y) Largest decline over 3 years	-88.66%	-16.78%	-71.88%
Max Drawdown (5Y) Largest decline over 5 years	-96.45%	-36.79%	-59.66%
Max Drawdown (10Y) Largest decline over 10 years	—	-74.93%	—
Current Drawdown Current decline from peak	-84.11%	-14.10%	-70.01%
Average Drawdown Average peak-to-trough decline	-59.62%	-37.73%	-21.89%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.08%	4.21%	+7.87%

Volatility

TXG vs. SBRA - Volatility Comparison

10x Genomics, Inc. (TXG) has a higher volatility of 16.46% compared to Sabra Health Care REIT, Inc. (SBRA) at 6.77%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than SBRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TXG	SBRA	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.46%	6.77%	+9.69%
Volatility (6M) Calculated over the trailing 6-month period	45.64%	14.88%	+30.76%
Volatility (1Y) Calculated over the trailing 1-year period	67.46%	19.77%	+47.69%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	68.25%	26.82%	+41.43%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	66.73%	36.40%	+30.33%

Dividends

TXG vs. SBRA - Dividend Comparison

TXG has not paid dividends to shareholders, while SBRA's dividend yield for the trailing twelve months is around 6.63%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
SBRA Sabra Health Care REIT, Inc.	6.63%	6.34%	6.93%	8.41%	9.65%	8.86%	7.77%	8.43%	10.92%	9.22%	6.84%	7.91%
TXG 10x Genomics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

TXG vs. SBRA - Profitability Comparison

The chart below illustrates the profitability comparison between 10x Genomics, Inc. and Sabra Health Care REIT, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

TXG - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, 10x Genomics, Inc. reported a gross profit of 106.18M and revenue of 150.84M. Therefore, the gross margin over that period was 70.4%.

SBRA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sabra Health Care REIT, Inc. reported a gross profit of 0.00 and revenue of 221.75M. Therefore, the gross margin over that period was 0.0%.

TXG - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, 10x Genomics, Inc. reported an operating income of -17.05M and revenue of 150.84M, resulting in an operating margin of -11.3%.

SBRA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sabra Health Care REIT, Inc. reported an operating income of 0.00 and revenue of 221.75M, resulting in an operating margin of 0.0%.

TXG - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, 10x Genomics, Inc. reported a net income of -13.47M and revenue of 150.84M, resulting in a net margin of -8.9%.

SBRA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sabra Health Care REIT, Inc. reported a net income of 39.95M and revenue of 221.75M, resulting in a net margin of 18.0%.

Frequently Asked Questions

Can I hold both TXG and SBRA in my portfolio?

TXG and SBRA have a correlation of -0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TXG or SBRA?

TXG has higher volatility (16.46%) compared to SBRA (6.77%). In terms of maximum drawdown, TXG dropped -96.47% vs SBRA's -99.49%.

Which has better risk-adjusted returns?

TXG currently has the higher Sharpe Ratio (3.81 vs 0.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.